{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:11:45Z","timestamp":1760281905700,"version":"build-2065373602"},"reference-count":9,"publisher":"Wiley","issue":"13","license":[{"start":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T00:00:00Z","timestamp":1493683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>Optimal outcomes with chronic myeloid leukemia treatment may not be attainable for those without health insurance or with Medicaid. Running the marathon journey of chronic myeloid leukemia requires the key element of adequate health insurance, in addition to proper monitoring and decision making, for the best results and the potential for treatment\u2010free remission.<\/jats:p><jats:p>See also pages 2561\u20109.<\/jats:p>","DOI":"10.1002\/cncr.30638","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T12:13:07Z","timestamp":1493727187000},"page":"2395-2397","source":"Crossref","is-referenced-by-count":0,"title":["Running the marathon of chronic myeloid leukemia with no shoes (or without the right shoes)!"],"prefix":"10.1002","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2251-4032","authenticated-orcid":false,"given":"Michael J.","family":"Mauro","sequence":"first","affiliation":[{"name":"Myeloproliferative Neoplasms Program, Leukemia Service, Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,2]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_2_4_3_1","unstructured":"National Comprehensive Cancer Network. NCCN guidelines for chronic myeloid leukemia (version 2.2017).https:\/\/www.nccn.org\/professionals\/physician_gls\/recently_updated.asp. Accessed January 23 2017."},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30639"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.9123"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.4184"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490003"},{"key":"e_1_2_4_10_1","first-page":"5s","article-title":"Cytogenetic and molecular testing in patients with chronic myeloid leukemia (CML) in a prospective observational study (SIMPLICITY) [abstract 7050]","volume":"32","author":"Goldberg SL","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.30638","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.30638","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:32:33Z","timestamp":1760279553000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,2]]},"references-count":9,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1002\/cncr.30638"],"URL":"https:\/\/doi.org\/10.1002\/cncr.30638","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2017,5,2]]}}}